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Abstract The tumor suppressor p53 has evolved a MDM2-
dependent feedback loop that promotes p53 protein deg-
radation through the ubiquitin–proteasome system. MDM2
is an E3-RING containing ubiquitin ligase that catalyzes
p53 ubiquitination by a dual-site mechanism requiring
ligand occupation of its N-terminal hydrophobic pocket,
which then stabilizes MDM2 binding to the ubiquitination
signal in the DNA-binding domain of p53. A unique
pseudo-substrate motif or “lid” in MDM2 is adjacent to its
N-terminal hydrophobic pocket, and we have evaluated the
effects of the flexible lid on the dual-site ubiquitination
reaction mechanism catalyzed by MDM2. Deletion of this
pseudo-substrate motif promotes MDM2 protein ther-
moinstability, indicating that the site can function as a
positive regulatory element. Phospho-mimetic mutation in
the pseudo-substrate motif at codon 17 (MDM2S17D)
stabilizes the binding of MDM2 towards two distinct
peptide docking sites within the p53 tetramer and enhances
p53 ubiquitination. Molecular modeling orientates the
phospho-mimetic pseudo-substrate motif in equilibrium
over a charged surface patch on the MDM2 at Arg97/
Lys98, and mutation of these residues to the MDM4
equivalent reverses the activating effect of the phospho-
mimetic mutation on MDM2 function. These data highlight
the ability of the pseudo-substrate motif to regulate the
allosteric interaction between the N-terminal hydrophobic
pocket of MDM2 and its central acidic domain, which
stimulates the E3 ubiquitin ligase function of MDM2. This
model of MDM2 regulation implicates an as yet undefined
lid-kinase as a component of pro-oncogenic pathways that
stimulate the E3 ubiquitin ligase function of MDM2 in cells.
Keywords MDM2 . p53 . Allostery . Kinase . Ubiquitination
Introduction
Reconstitution of a multicomponent ubiquitin–enzyme
reaction mechanism, including the role of E1, E2, and E3
subcomponents as well as the substrate, is a fundamental
goal in understanding the molecular events that regulate the
ubiquitin–proteasome pathway [32]. The proteins within
the E3 class of ubiquitination catalysts include among
others the HECT domain and the RING domains. Unlike
J Chem Biol (2009) 2:113–129
DOI 10.1007/s12154-009-0019-5
E. G. Worrall : T. R. Hupp
CRUK p53 Signal Transduction Group, University of Edinburgh,
Edinburgh, Scotland, UK, EH4 2XR
B. Wawrzynow :K. L. Ball
CRUK Interferon and Cell Signaling Group,
University of Edinburgh,
Edinburgh, Scotland, UK, EH4 2XR
E. G. Worrall :B. Wawrzynow :K. L. Ball : T. R. Hupp (*)
Institute of Genetics and Molecular Medicine,
University of Edinburgh,
Edinburgh, Scotland, UK, EH4 2XR
e-mail: ted.hupp@ed.ac.uk
L. Worrall
Institute for Translational and Chemical Biology,
University of Edinburgh,
Edinburgh, Scotland, UK, EH4 2XR
M. Walkinshaw
Institute for Translational and Chemical Biology,
University of Edinburgh,
Edinburgh, Scotland, UK, EH9 3JR
Present Address:
L. Worrall
Biochemistry and Molecular Biology and the Center for Blood
Research, University of British Columbia,
Vancouver, British Columbia, Canada, V6T 1Z3
the HECT domain containing ubiquitin ligases, the E3-
RING domain containing proteins do not form a covalent
bond with ubiquitin, but catalyze the transfer of ubiquitin
from the activated E2 to the substrate by as yet undefined
mechanisms. How E3-RING domain containing ubiquitin
ligases alter substrate conformation and drive E2 recogni-
tion of substrate are critical mechanistic goals. The pro-
oncogenic protein MDM2 is such a RING domain contain-
ing E3 ubiquitin ligase that can promote the ubiquitination
of the p53 tumor suppressor protein [44, 49], and MDM2
represents a model E3 ubiquitin ligase to evaluate the
dynamics of a multiprotein ubiquitination system.
The E3-RING domain containing ubiquitin ligase MDM2
itself has been dissected into multiple domains with specific
biochemical functions. The C-terminal RING domain in
MDM2 co-ordinates the activity of MDM2 in E2-mediated
ubiquitin transfer [22] and contains a C-terminal peptide tail
that maintains RING-domain conformation [36, 46]. The
RING domain also promotes MDM2-dependent stimulation
of p53 protein synthesis through interactions with p53
mRNA during translation [7], and RNA itself can stimulate
MDM2:p53 interactions and substrate ubiquitination [5, 6,
33]. There also is an ATP-binding motif imbedded within
the RING domain that regulates the molecular chaperone
functions of MDM2 [41, 51]. Thus, the RING domain of
MDM2 mediates biochemical functions, including E2
binding, ATP binding, and RNA binding.
In addition to the C-terminal RING domain, MDM2 also
contains an N-terminal allosteric hydrophobic pocket,
which interacts with a specific linear peptide motif in
proteins such as p53 and interferon-responsive transcription
factors [20, 33]. This hydrophobic pocket was the first
region on MDM2 that was shown to bind directly to p53
[8]. Adjacent to this N-terminal domain is an “acidic”
domain that interacts at a second binding site within a
flexible motif in the DNA binding domain of p53 [38]. The
N-terminal hydrophobic binding pocket has been targeted
by small molecules like Nutlins that can interact with
MDM2 and activate p53 function by releasing p53 from
MDM2-mediated transrepression [47]. However, such
ligands do not block p53 ubiquitination [50] as ligand
occupation of this N-terminal hydrophobic pocket forms a
positive role in MDM2 function as an E3 ubiquitin ligase.
MDM2 hydrophobic pocket occupation promotes a more
stable interaction between the internal acidic domain of
MDM2 and a ubiquitination signal in the DNA-binding
domain of p53 [50].
These data have formed a “dual-site” model of MDM2-
mediated ubiquitination of p53. Accordingly, small peptides
derived from the BOX-I domain of p53 (containing the
primary MDM2 binding site) or small molecules like Nutlin
do not block p53 ubiquitination. By contrast, peptides
derived from the BOX-V domain of p53 (containing the
ubiquitination signal in the DNA-binding domain of p53)
do inhibit MDM2 ubiquitination of p53 [50]. Allosteric
interactions within full-length MDM2 protein has been
recently examined through structure-function studies dem-
onstrating that mutation of selected amino acids in the
RING domain promotes a conformation change both in the
N-terminal domain of MDM2 as defined by proteolytic
cleavage susceptibility and in the acidic domain as defined
by elevated intrinsic tryptophan fluorescence [52]. These
latter data provided the first biophysical evidence for
allosteric interactions among the various sub-domains in
full-length MDM2 protein.
This dual-site model for MDM2-mediated ubiquitination
of p53 presumably operates due to the striking flexibility of
the N-terminal p53-binding domain in the presence of
distinct peptide ligands [37, 40, 45]. A predominant feature
of this ubiquitination reaction mechanism is that there is an
induced stabilization of the acidic domain of MDM2 to the
conformationally flexible region in the DNA-binding
domain of p53 [38, 55] when the MDM2 hydrophobic
pocket is occupied by substrate [50]. This linear peptide
motif in the DNA-binding domain of p53 (named BOX-V
motif) is normally cryptic in the folded p53 tetramer, but it
is exposed on mutant p53 in human cancers as defined
using a monoclonal antibody that binds to this peptide-
epitope on denatured p53 protein [13, 48].
This flexible BOX-V motif in the DNA-binding domain
of p53 is also a multiprotein docking site; many protein
kinases, including CHK1/2, DAPK, and CK1, interact with
this region on p53 to catalyze phosphorylation of the
transactivation domain of p53 at Ser20 [9, 23]. Destabiliz-
ing mutations in p53 that “unfold” p53 protein at the
conformationally flexible region of p53 in the BOX-V
domain enhance mutant p53 protein ubiquitination in cell
systems [39] and can induce mutant p53 degradation via
MDM2 function in murine transgenes [42]. The enhanced
degradation of mutant p53 protein by an MDM2-dependent
pathway has important implications for regulating the pro-
oncogenic functions of mutant p53 in human cancers;
indeed, most human cancers appear to have a form of
mutant p53 protein with enhanced steady-state levels [30]
and therefore has presumably evaded the normal mutant
protein degradation machinery.
In order to define further the nature of the allosteric
regulation of MDM2, we have examined the function of a
flexible and unstructured N-terminal peptide motif adjacent
to the hydrophobic pocket of MDM2. Such small flexible
peptide motifs have been postulated to be important in a
wide range of signaling proteins [27–29]. This flexible
motif in MDM2 has been called a pseudo-substrate motif or
lid. Pseudo-substrate motifs operate in a range of alloste-
rically regulated enzymes, including protein kinases and
metabolic enzymes, and have been termed intrasteric
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regulatory motifs [1, 16, 17]. The pseudo-substrate motif of
MDM2 harbors a phosphorylation site whose phospho-
mimetic mutation can alter the conformation of the N-
terminal domain of MDM2 protein as defined by NMR
studies [25, 40]. This phospho-mimetic mutation was
proposed to stabilize the pseudo-substrate motif over the
hydrophobic pocket and occlude p53 binding. However,
this has not been tested experimentally. As ligands that fill
the hydrophobic pocket like Nutlin can prime MDM2 and
stimulate the MDM2 E3 ubiquitin ligase function toward
p53 [50], the role of the unphosphorylated or phosphory-
lated lid is not necessarily evident—would it function as a
positive or negative cofactor in regulating the stability of
the MDM2:p53 complex, and therefore, would it ultimately
stimulate or attenuate p53 protein ubiquitination?
In this report, we show that the flexible lid is a positive
regulatory motif that maintains the thermostability of
MDM2 and that a phospho-mimetic mutation in the
MDM2 lid stabilizes the MDM2:p53 complex. We propose
a cis-acting intrasteric mechanism to explain how phospho-
mimetic mutation of the MDM2 lid might open the
hydrophobic pocket. This results in enhanced binding of
MDM2 to the first site on p53, which in turn enhances the
allosteric interaction between the acidic domain of MDM2
and the ubiquitination signal in the DNA-binding domain
of p53. These data also highlight the growing realization
that flexible and unstructured linear peptide motifs play
critical roles in controlling protein function in signal
transduction pathways [29] and provide a biochemical
foundation to study how changes in the rates of MDM2
phosphorylation at this flexible motif regulates the E3
ubiquitin ligase function of MDM2.
Results
A phospho-mimetic mutation in the pseudo-substrate motif
stimulates the E3 ubiquitin ligase function of MDM2
MDM2 is composed of distinct ligand binding domains that
regulate its multiple functions (Fig. 1). The integration of
our current study on the MDM2 pseudo-substrate motif to
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Fig. 1 Four distinct modes of MDM2 function. The top panel
highlights the domain structure of MDM2, including the hydrophobic
pocket in the N-terminus [20], the acidic central domain [55], a zinc-
binding motif [56], the RING domain [18], and ATP-binding site
imbedded within the RING domain [35]. MDM2 was identified as a
protein that regulates the p53 tumor suppressor via (1) inhibition of
p53-dependent transcription [26, 43]. Germline mutations in the mdm2
promoter that result in MDM2 over-production result in enhanced
MDM2 protein in chromatin fractions, which mediates suppression of
p53 function as a transcription factor [2, 52]. The second function
identified for MDM2 involved its ability to (2, 3) catalyze p53
degradation through a ubiquitin-dependent pathway [19] [15]. This
ubiquitination function of MDM2 also involves ubiquitination and
degradation of ribosomal proteins that can normally function to
stimulate p53 protein synthesis [31]. According to the dual-site
mechanism of MDM2-mediated ubiquitination of p53 [50], two
structural changes can enhance p53 ubiquitination by MDM2: one
structural change involves (2) destabilizing missense mutations in p53
that unfolds the p53 tetramer and that can expose the ubiquitination
signal in the DNA-binding domain [38], thus enhancing p53
ubiquitination in cells [39]; the second structural change involves (3)
the lid of MDM2 whose phospho-mimetic mutation increases MDM2-
mediated ubiquitination of p53 tetramers by stabilizing the MDM2:
p53 complex (this study). Small molecules that bind to the N-terminal
hydrophobic pocket of MDM2 (Nutlins) can activate p53 [47]
presumably by inhibiting the chromatin-bound pool of MDM2 since
Nutlins cannot inhibit MDM2 function as an E3 ubiquitin ligase [50].
Rather, to date, peptide mimetics that bind to the MDM2 acidic
domain provide a lead for inhibiting MDM2 function as a E3 ubiquitin
ligase [50]. Additional research has highlighted novel molecular
functions of MDM2. A cellular function was assigned to the RNA-
binding activity of MDM2 [12, 21, 24], which involves (4) an
interaction of MDM2 with p53 mRNA at ribosomes to stimulate p53
protein synthesis [7]. A function was also assigned to the ATP-binding
motif of MDM2 [35], which involves (5) the ability of MDM2 to
exhibit the property of a molecular chaperone by catalyzing the ATP-
dependent folding of the p53 tetramer to enhance p53 function as a
transcription factor [41, 51]
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the known biochemical functions of MDM2 is also
summarized in Fig. 1. The MDM2 oncoprotein is known
to have diverse molecular functions in (1) transcriptional
repression of p53, (2) ubiquitination and degradation of
p53, (3) synthesis of p53 protein, and (4) ATP-dependent
molecular chaperone functions on p53 protein (Fig. 1). It is
not known if these four functions are integrated, function in
parallel, or are coordinately switched on or off. However,
human and mouse genetic studies have established a
specific role for the RING domain and hydrophobic pocket
in the control of MDM2 function as a transrepressor and as
an E3 ubiquitin ligase [2, 44].
In order to dissect further the dual-site model of MDM2-
mediated ubiquitination of p53, we focused our analysis on
the effects of the pseudo-substrate motif (Fig. 2a) on the in
vitro E3 ubiquitin ligase function of MDM2. An NMR
study of the unliganded apo-form of the N-terminal domain
of MDM2 revealed the pseudo-substrate motif to be largely
unstructured and in a dynamic equilibrium (Fig. 2b).
Further, ligands that occupy the hydrophobic pocket can
alter the conformation of MDM2 [25, 37, 40, 45],
highlighting the conformational flexibility of MDM2.
However, ligands such as Nultin or a p53 peptide (BOX-I
domain peptide) do not inhibit MDM2-mediated ubiquiti-
nation (Fig. 2c and d), while peptides that bind to the acidic
domain of MDM2 (BOX-V domain homology peptides) can
inhibit MDM2 function (Fig. 2e; as in [33, 50, 52]). As the
conformational flexibility of this N-terminal pseudo-
substrate motif of MDM2 could have significant regulatory
effects on MDM2 conformation, this motif also provides a
novel tool with which to evaluate how perturbation of the
hydrophobic pocket of MDM2 might regulate allosterically
the E3 ubiquitin ligase function of MDM2.
To define a role for this flexible pseudo-substrate motif or
lid, purified untagged wild-type MDM2 and MDM2
mutants were generated, including one with an N-terminal
flexible pseudo-substrate motif deletion (MDM2ΔLID;
Fig. 3a). A titration of MDM2 (Fig. 3b, lanes 1–5) or
MDM2ΔLID (Fig. 3b, lanes 6–10) in ubiquitination
reactions demonstrated that MDM2ΔLID has a lower
specific activity, although it can still catalyze ubiquitina-
tion. The lowered specific activity of MDM2ΔLID suggests
the pseudo-substrate motif normally has an intrinsic
positive regulatory effect on MDM2 function.
The pseudo-substrate motif also has a SQ phospho-
acceptor site whose phospho-mimetic mutation (S to D)
induces a conformational change in the N-terminal domain of
MDM2 as defined using NMR [25] (Fig. 2a and b). This
mutation was predicted to stabilize the lid equilibrium into a
position that partially occludes ligands like p53 and that this
mutation might therefore block the MDM2:p53 complex.
However, the biochemical effects of this mutation on
MDM2 function in vitro and in vivo have not actually been
defined experimentally. As such, we also evaluated the
effect of the phospho-mimetic pseudo-substrate motif
mutant (MDM2S17D; Fig. 3a) on MDM2:p53 interactions.
Three possibilities include (1) that the phospho-mimetic
motif could act like a lid and partially cover the
hydrophobic pocket, thus destabilizing the MDM2–p53
interaction [25]; (2) the phospho-mimetic motif could act
like a lid and partially cover the hydrophobic pocket, thus
stabilizing MDM2 acid domain interactions with p53 via
the dual site allosteric model [50]; and (3) the phospho-
mimetic mutation might stabilize the lid in equilibrium in
a distinct conformation and “open” the hydrophobic
pocket (Fig. 2b). The phospho-mimetic mutation in
MDM2 in fact did not inhibit the ubiquitination function
of MDM2; rather, the Asp17 mutation increased the
specific activity of MDM2 as an E3 ubiquitin ligase
(Fig. 3c, lanes 5–7 vs 2–4 and d).
These data are consistent with the lid functioning as a
positive rather than as a negative regulatory motif.
Regulatory motifs often alter the thermostability of an
enzyme or protein [11], and we evaluated whether the
pseudo-substrate motif deletion alters thermostability of
MDM2. The preincubation of MDM2ΔLID at the indicated
temperatures completely inactivated the E3 ubiquitin ligase
function of the protein (Fig. 3e, lanes 8–12 vs 7). MDM2S17D
was not thermosensitive when preincubated at elevated
temperatures compared to MDM2ΔLID (Fig. 3f). These data
suggest that the pseudo-substrate motif contributes positively
to maintaining the thermostability of MDM2 protein.
Consistent with this, transfection of the plasmid encoding
MDM2ΔLID into cells destabilizes the protein and accord-
ingly reduces its specific activity as an E3 ubiquitin ligase
toward p53 (Fig. 3g, lanes 6–8 vs 3–5).
A phospho-mimetic mutation in the pseudo-substrate motif
stabilizes MDM2:p53 interactions
We next analyzed whether the elevated specific activity of
MDM2S17D as a E3 ubiquitin ligase could be attributed to
enhanced binding of MDM2 to p53 protein resulting in a
more stable MDM2:p53 protein complex. This enhanced
stability of the MDM2:p53 complex would in turn translate to
enhanced p53 ubiquitination. A titration of MDM2S17D, wt-
MDM2, or MDM2ΔLID provided a correlation between
specific activity of an E3 ubiquitin ligase and enhanced
stability of the MDM2:p53 protein complex (Fig. 4b).
Although MDM2ΔLID was essentially unable to form a stable
contact with the p53 tetramer presumably as a result of
pseudo-substrate motif deletion, MDM2S17D exhibited a
striking increase in its binding for p53 protein as defined by
the stability of the MDM2:p53 complex (Fig. 4b). The
preincubation of MDM2S17D, wt-MDM2, or MDM2ΔLID at
distinct temperatures had no effect in altering wt-MDM2
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protein or MDM2S17D interactions with p53 (Fig. 4c). This
elevated stability of the MDM2:p53 complex as a result of the
Asp17 mutation in MDM2 is consistent with the enhanced E3
ubiquitin ligase activity of MDM2S17D (Fig. 3). However,
these data are not compatible with the hypothesis that this
phospho-mimetic substitution would destabilize the MDM2:
p53 interactions [25].
The data presented above showing that the phospho-
mimetic S17D substitution of MDM2 stabilizes the MDM2:
p53 interaction could be explained by two models consistent
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The pseudo-substrate motif is
surrounded by a box, and the
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b The NMR structure of the
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highlighted with arrows, and
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substrate motif interacting with
the MDM2 surface are high-
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highlighted with arrows and
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with the dual site docking model of MDM2 function [50]; (1)
the phospho-mimicking pseudo-substrate motif is indeed
partially occluding the hydrophobic binding pocket [25], but
is acting in a positive auto-allosteric manner (i.e., like Nutlin
[50]), or (2) the S17D mutation orientates the pseudo-
substrate motif in a position that stabilizes the N-terminal
domain of MDM2 in an open conformation with the pseudo-
substrate motif in equilibrium at a position outwith the
hydrophobic pocket (Fig. 2b, asterisks). The striking
conformational flexibility of MDM2 when peptide ligands
of differing length occupy the pocket [37] or when the lid is
in distinct conformations [40] is consistent with either of
these two models. We carried out further biochemical
characterization of MDM2S17D in order to distinguish
between these two models.
One method to examine whether the Asp17 mutation
stabilizes the pseudo-substrate motif over the hydrophobic
pocket of MDM2 or whether the mutation opens the
hydrophobic pocket by shifting lid equilibrium would be
to determine whether MDM2S17D is sensitive or resistant to
Nutlin. It could be predicted that MDM2S17D cannot
interact with Nutlin (or the BOX-I domain of p53) if the
Asp17 modified pseudo-substrate motif is stabilized over
the hydrophobic pocket. However, Nutlin destabilizes the
MDM2S17D:p53 complex as well as the wt-MDM2:p53
complex (Fig. 5b and c). Although these data might not be
compatible with the model that the Asp17 substituted
pseudo-substrate motif is partially stabilized over the
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Fig. 3 A phospho-mimetic substitution in the MDM2 lid stimulates the
E3 ubiquitin ligase function of MDM2. a Diagram of the functional
domains of MDM2, including (1) wt-MDM2; (2) MDM2ΔLID, which
has a deletion of the flexible motif; and (3) MDM2S17D, which has a
phospho-mimetic aspartate mutation at Ser17 (S17D). bMDM2-pseudo-
substrate motif deletion reduces the specific activity of MDM2. Purified
wt-MDM2 or MDM2ΔLID was titrated directly into ubiquitination
reactions using p53 as a substrate. After 10 min, the reactions were
stopped and processed for immunoblotting to measure extents of p53
ubiquitination. c The S17D mutation in the MDM2 pseudo-substrate
motif stimulates its E3 ubiquitin ligase function. Purified wt-MDM2
(lanes 2–4) or MDM2S17D (lanes 5–7) were titrated directly into
ubiquitination reactions using p53 as a substrate. After 10 min, the
reactions were stopped and processed for immunoblotting to measure
extents of p53 ubiquitination, which is quantified in d. eMDM2-pseudo-
substrate motif deletion promotes thermoinstability in MDM2. Purified
wt-MDM2 or MDM2ΔLID was added directly to ubiquitination reactions
(lanes 1 and 7) or was preincubated at increasing temperatures (0–50°C)
in ubiquitination buffer (lanes 2–6 and 8–12) followed by titration in
ubiquitination reactions using p53 as a substrate. After 10 min, the
reactions were stopped and processed for immunoblotting to measure
extents of p53 ubiquitination. f S17D mutation in the MDM2 pseudo-
substrate motif does not destabilize MDM2. Purified MDM2S17D was
preincubated at increasing temperatures (0–50°C) in ubiquitination
buffer followed by titration in ubiquitination reactions using p53 as a
substrate. After 10 min, the reactions were stopped and processed for
immunoblotting to measure extents of p53 ubiquitination. g MDM2-
pseudo-substrate motif deletion promotes MDM2 instability in cells. P53
was co-transfected into cells with his-tagged ubiquitin and vector control
(lane 2) or increasing amounts of MDM2 (lanes 3–5) or MDM2ΔLID
(lanes 6–8). The reactions were processed to measure p53 ubiquitination
as indicated [39]

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hydrophobic pocket of MDM2, modeling data have shown
that if the phospho-mimetic lid does occlude the hydropho-
bic pocket, it does so only in the entry region of the N-
terminal p53 peptide [40]. Thus, we evaluated whether the
MDM2S17D has a higher or lower binding activity for the
p53 peptide itself derived from the BOX-I domain.
As seen with the full-length p53 tetramers, MDM2S17D
also binds more stably to the BOX-I peptides, relative to wt-
MDM2 (Fig. 6c and d). The BOX-I peptide “a” is the
naturally occurring peptide from p53, while BOX-I peptide
“b” is the optimized higher affinity peptide named 12.1
identified using combinatorial peptide libraries [4]. This
enhanced binding of MDM2S17D to the BOX-I peptide from
p53 again is not compatible with the model that the Asp17
pseudo-substrate motif is stabilized over the hydrophobic
pocket, and if this were the case, then MDM2S17D should
have a lower binding activity for the p53 BOX-I peptide. As
a control, MDM2ΔLID cannot form a stable complex with the
BOX-I peptide (Fig. 6c and d), although MDM2ΔLID can
form a stable complex with the ubiquitination signal within
the BOX-V peptide from p53 (Fig. 6f and g). These latter
data indicate that the integrity of the acidic domain of
MDM2 is maintained to a significant degree in MDM2ΔLID.
Furthermore, the MDM2S17D is also more active in binding
to the BOX-V peptide that wt-MDM2 (Fig. 6f and g), which
together explains in part why MDM2S17D binds better to the
p53 tetramer (Fig. 4b and c). These data also suggest that
conformational changes in the N-terminal hydrophobic
pocket of MDM2 as a result of the phospho-mimetic lid
mutation are transferred to the acidic domain of MDM2,
which is consistent with the dual-site model of MDM2-
mediated ubiquitination of p53.
A single missense mutation of the RING domain of
MDM2 changes the conformation of both the hydrophobic
pocket and the acidic domain [52]. We evaluated further
this intra/interdomain allosteric interaction in MDM2S17D
protein by examining its binding activity for BOX-I- and
BOX-V-derived p53 peptides in the absence and presence of
Nutlin. A Nutlin titration into reactions containing wt-
MDM2 or MDM2S17D indicated that Nutlin is able to
compete with MDM2 binding to the BOX-I-derived peptide
(Fig. 7b and c), as expected. However, quantitative differ-
ences are observed in this reaction. MDM2S17D protein is
more sensitive in its binding to the BOX-I peptide in the
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Fig. 4 A phospho-mimetic substitution in the MDM2 lid stabilizes
MDM2:p53 tetramer complex formation. a Strategy for measuring the
stability of the MDM2:p53 complex. Tetrameric forms of p53 protein
were adsorbed onto the solid phase (in red) followed by MDM2
titration (gray). The stability of MDM2 bound to p53 tetramers was
measured using a monoclonal antibody specific for MDM2 by
chemiluminescence. b The S17D mutation in the MDM2 pseudo-
substrate motif stabilizes the MDM2:p53 tetrameric complex. Increas-
ing amounts of the indicated MDM2 protein (wt-MDM2, MDM2ΔLID,
or MDM2S17D) were titrated into reactions where fixed amounts of
tetrameric p53 were on solid phase as described previously [38]. The
extent of MDM2 binding was quantified using an anti-MDM2
monoclonal antibody and binding stability depicted using enhanced
chemiluminescence in relative light units (RLU). c Elevated temper-
ature does not alter the activating effect of S17D mutation on MDM2:
p53 complex stability. MDM2 was preincubated at distinct temper-
atures, as indicated, and binding activity to the p53 tetramer was
measured as described above in RLU
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presence of Nutlin relative to wt-MDM2, consistent with
the model that the phospho-mimetic mutation opens the
hydrophobic pocket. Another prediction of this allosteric
model would be that Nutlin would alter the binding activity
of MDM2S17D to the BOX-V-domain-derived peptides. This
is observed experimentally; although the BOX-I peptide can
partially destabilize MDM2S17D:BOX-V peptide complexes
(Fig. 7e), Nutlin completely destabilizes this interaction
(Fig. 7f). The acute sensitivity of the MDM2:p53 tetrameric
complex to Nutlin (Fig. 5) can therefore be explained
because not only does Nutlin destabilize the MDM2:BOX-I
peptide complex by direct competition but it can also
destabilize the MDM2:BOX-V peptide complex by alloste-
ric effects as suggested previously [52].
Mutation of basic residues in the hydrophobic domain
is dominant over Asp17 and inactivates MDM2S17D
Together, the data allow the formation of a model, whereby
the Asp17 substitution does change the conformation of
MDM2 [25], but it does so by “opening” the hydrophobic
pocket. One model to explain why the phospho-mimetic
mutation in the MDM2 lid stabilizes MDM2:p53 interac-
tions is that the phospho-amino acid is stabilized by
interactions with a second binding site on MDM2 (as in
Fig. 2b, asterisks). NMR analysis shows that, in compar-
ison to the peptide bound form, the N-terminal domain of
apo-MDM2 is more unstructured and flexible, especially
the regions surrounding the peptide binding cleft [45]. The
unliganded structure shows a narrow, shallow binding
groove as a result of the closer association of the two sub-
domains. As suggested previously [25], some conformers
show MDM2 residues 18–24 can have helical character and
partially occlude the shallow end of the p53 binding cleft
(Fig. 8b). The remainder of the binding pocket, however, is
not occupied by the remainder of the pseudo-substrate
motif [25], and further, conformers show this region
unwound and more displaced from the binding pocket
(Fig. 2b, asterisks). This conformational heterogeneity of
the pseudo-substrate motif eludes to a dynamic equilibrium
between more structured conformations occupying part of
the binding groove and less ordered states removed from
binding pocket. The mutual occupancy of the p53 peptide
and the pseudo-substrate domain is excluded (Fig. 8b), and
p53
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Fig. 5 Nutlin destabilizes the MDM2S17D:p53 tetramer complex. a
Strategy for measuring the stability of the MDM2:p53 complex in the
presence of small ligands. Tetrameric forms of p53 protein were
adsorbed onto the solid phase (in red) followed by MDM2 titration
(gray) in the absence or presence of the indicated inhibitors, including
(1) Nutlin-3, (2) BOX-Ia peptides, (3) BOX-Va or BOX-Vb peptides,
and (4) DMSO carrier. The stability of MDM2 bound to p53 tetramers
was measured using a monoclonal antibody specific for MDM2 by
chemiluminescence. b and c MDM2S17D binding to p53 is not
inhibited by Nutlin. MDM2 (b) or MDM2S17D (c) was assembled
into reactions containing the indicated ligand: BOX-I peptide, BOX-V
peptides, or Nutlin. The mixture was added to tetrameric p53 protein
on the solid phase, and the amount of MDM2 bound stably to p53 was
quantified using an MDM2 monoclonal antibody. The stability of the
MDM2:p53 complex is depicted in relative light units
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p53 would preferentially bind to the N-terminal domain of
MDM2 when the D17-pseudo-substrate domain was dis-
placed from the binding site (Fig. 8c and d).
The increased ligand binding activity of MDM2S17D
could thus be explained by the mutation causing a shift in
equilibrium toward a more open conformation primed for
peptide binding. In fact, the phospho-pseudo-substrate
motif peptide of MDM2S17D has a higher binding activity
for MDM2 compared to wild-type peptide [25], and the
phospho-mimetic mutation may preferentially bind to a
cationic region on the MDM2 surface. Inspection of the
MDM2 apo-structure NMR ensemble reveals that the
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Fig. 6 Phospho-mimetic substi-
tution in the MDM2 lid motif
enhances MDM2 binding activity
for BOX-I and BOX-V peptide
ligands. a The domain structure
of MDM2 minidomains, relative
to p53 minidomains containing
the BOX-I and BOX-V docking
regions is highlighted. The panel
highlights (a) an interaction be-
tween the N-terminal MDM2
domain (N) and the p53 BOX-I
motif (I) and (b) an interaction
between the acid domain of
MDM2 (AD) and the BOX-V
motif of p53 (V). b The assay
was designed to measure the
interaction between the N-
terminal domain of full-length
MDM2 and the BOX-I-derived
p53 peptide. c and d MDM2S17D
has an enhanced binding activity
for the BOX-I domain of p53.
wt-MDM2, MDM2ΔLID, or
MDM2S17D proteins were titrated
into reaction buffer and incubat-
ed onto the solid phase contain-
ing BOX-I a peptide (left panel)
and BOX-I b peptide (right
panel). The amount of MDM2
bound stably to the p53 peptides
was quantified using an MDM2
monoclonal antibody. The stabil-
ity of the MDM2:p53 complex is
depicted in relative light units.
e The assay was designed to
measure the interaction between
the central acidic domain of
full-length MDM2 and the BOX-
V-derived peptides. f and
g MDM2S17D has an enhanced
binding activity for the BOX-V
domain of p53. wt-MDM2,
MDM2ΔLID, or MDM2S17D
proteins were titrated into
reaction buffer and incubated
onto the solid phase containing
BOX-V a peptide (left panel) and
BOX-V b peptide (right panel).
The amount of MDM2 bound
stably to the p53 peptides was
quantified using an MDM2
monoclonal antibody. The
stability of the MDM2:p53
complex is depicted in relative
light units
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conformationally heterogeneous pseudo-substrate motif can
be in proximity to a positively charged region at the N-
terminal part of helix α2′ composed of His96, Arg97, and
Lys98, which could complex acidic residues (Fig. 8c and d).
Binding of Asp17 to this positively charged region may help
stabilize the pseudo-substrate motif away from the binding
groove and shift the equilibrium toward a conformation
favorable for peptide binding by MDM2.
In regard to this equilibrium model, it is interesting to note
that the His96, Arg97, and Lys98 equivalent residues of
MDM4 are altered, thus removing a potentially cationic
interface (Fig. 9a). This might give clues to residues that
have co-evolved with the MDM2 pseudo-substrate motif,
which is also absent in MDM4. To disrupt this positively
charged patch (Fig. 9a), we created an MDM2 mutant which
contains the Arg97Lys98 mutated to the MDM4 equivalent of
Ser97Pro98 (Fig. 8a). MDM4 has been shown to have a
conserved structure with MDM2 and bind p53 peptides in
the same manner and with comparable affinities [34]. A
titration of the wt-MDM2 and MDM2R97S:K98P demonstrated
that the basic substitutions maintain an equivalent ability of
MDM2 to bind to tetrameric p53 (Fig. 8e), reduced
interactions with the p53 BOX-I peptide (Fig. 8f), and
maintain equivalent binding activity of MDM2 for the p53
BOX-V peptide (Fig. 8g). These data indicate that the
Ser97Pro98 substitutions do not disrupt fundamentally the
core folding of the hydrophobic domain, not the allosteric
interactions with the acidic domain of MDM2.
By contrast, the enhanced binding ofMDM2S17D to the p53
tetramer is completely eliminated in the MDM2S17D:R97S:K98P
triple mutant (Fig. 9c). Further, the MDM2S17D:R97S:K98P triple
mutant is unable to form a stable complex with the p53 BOX-I
peptide (Fig. 9d), but can still bind to the BOX-V peptide
(Fig. 9e). Thus, the R97S:K98P double mutations can convert
MDM2S17D protein from an activated to an inhibited form,
under conditions where the MDM2 R97S:K98P double
mutant remains active. This inactivated triple mutant is
consistent with the model that mutation of the basic patch
stabilizes the phospho-mimetic lid over the hydrophobic
pocket, which is not compatible with p53 binding (Fig. 9b).
MDM2 bound to BOXVb MDM2 bound to BOXVb
MDM2 bound to BOXIb MDM2 bound to BOXIb
a b c
d e f
Fig. 7 Nutlin destabilizes the MDM2:p53 BOX-I and BOX-V peptide
complex. a Strategy for measuring the stability of the MDM2:p53
BOX-I peptide complex in the presence of small ligands. The
biotinylated BOX-Ib peptide was adsorbed onto the streptavidin-
coated solid phase followed by wt-MDM2, MDM2ΔLID, or
MDM2S17D proteins titration in the absence or presence of the
indicated inhibitors, including b the BOX-Ib peptide and c Nutlin-3.
The stability of MDM2 bound to the BOX-I peptide was measured
using a monoclonal antibody specific for MDM2 by chemilumines-
cence and is depicted in relative light units. d Strategy for measuring
the stability of the MDM2:p53 BOX-V peptide complex in the
presence of small ligands. The biotinylated BOX-Vb peptide was
adsorbed onto the streptavidin-coated solid phase followed by wt-
MDM2, MDM2ΔLID, or MDM2S17D proteins titration in the absence
or presence of the indicated inhibitors, including e the BOX-Ib peptide
and f Nutlin-3. The stability of MDM2 bound to the BOX-V peptide
was measured using a monoclonal antibody specific for MDM2 by
chemiluminescence and is depicted in relative light units
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Discussion
MDM2 is a multidomain E3 RING-finger ubiquitin ligase and
represents a model protein with which to define mechanisms of
substrate ubiquitination. The recent dual-site model forMDM2-
mediated ubiquitination of p53 suggested an allosteric compo-
nent to the E3 ubiquitin ligase function, which invokes MDM2
docking to two distinct sites on p53: the BOX-I transactivation
domain and a conformationally flexible motif in the BOX-V
domain of p53. The allostery in the N-terminal domain that
operates toward the acidic domain [50] can be propagated
presumably via the striking conformational flexibility of the
N-terminal domain of MDM2 as defined by NMR [25, 37,
45]. The unexpected feature of the dual site model was that
the N-terminal hydrophobic pocket of MDM2 can act as an
allosteric ligand binding site and that ligands like Nutlin can
prime MDM2 and “activate” the E3 ubiquitin ligase function
of MDM2 [50]. The allosteric interactions have been further
linked to the RING domain, as certain mutation in the RING
can induce conformational changes in both the hydrophobic
pocket and the central acidic domain [52].
A novel model can be developed that incorporates the
various biochemical and biophysical studies of the flexible
N-terminal domain of MDM2 and which supports an
equilibrium model for pseudo-substrate motif function. As
originally suggested [25] and later confirmed in the NMR
structure of apo-MDM2 [40, 45], the N-terminal segment
of MDM2 can partially occlude the shallow end of the p53-
binding cleft (Fig. 8b); however, this motif is not well
structured, and the remainder of the binding pocket remains
empty, at least in the non-phosphorylated state. In this
conformation, Ile19 occupies much of the space taken up by
Pro27 of the p53 peptide chain [20] and as such excludes
the mutual occupancy of the pseudo-substrate motif and
p53. Interestingly, Ile19 is the only residue in the N-terminal
region that exhibits any significant interaction with the rest
of apo-MDM2 [45], forming hydrophobic contacts with
His96, Arg97, and Tyr100 in the N-terminal part of α2′. In
some NMR conformers, Ile19 is displaced from the site
occupied by Pro27, forming a more intimate association
with the N-terminal region of helix α2′. Based on this, we
have proposed that the pseudo-substrate motif exists in
dynamic equilibrium between states that are incompatible
with or compatible with p53 peptide binding; p53 can only
bind when the pseudo-substrate motif has dissociated from
the hydrophobic binding site. In favor of this equilibrium,
both NMR studies indicated several residues within the
pseudo-substrate domain and the region surrounding helix
α2′ that behaved as though in slow conformational
exchange [25, 45]. Furthermore, it is interesting to note
that the shorter p53 peptide, lacking residues 27–29, which
share an overlapping binding site with the pseudo-substrate
motif, binds to MDM2 with a ten-fold higher affinity [37].
Thus, in order for p53 to bind to MDM2, the following
events need to occur possibly in a concerted fashion;
residues 19–25 forming the pseudo-substrate motif must
dissociate from one end of the groove and be replaced by
segments 27–29 of the incoming p53; the two MDM2
subdomains swing apart from one another by 3–4Å; during
the process of binding, strand β3′ is formed, completing the
terminal (β1, β2, β3′) sheet that caps one end of the groove
and helps to hold the two subdomains in their new more
rigid conformation. However, deletion of the flexible lid
destabilizes the N-terminal domain of MDM2 (this study),
so this motif also has a positive role to play in the MDM2-
p53 interaction. In addition to these ordered and sequential
changes in MDM2-substrate binding, our current study
suggests an activating model for the function of the flexible
pseudo-substrate motif upon phosphorylation, which
enhances displacement of the pseudo-substrate domain by
altering its equilibrium, thus opening the groove to stabilize
p53-peptide binding to MDM2 (Fig. 10). This conforma-
tional change upon hydrophobic pocket occupation by its
ligand then appears to be propagated to the central acidic
domain of MDM2 that results in enhanced MDM2
interactions with p53 (Fig. 10).
MDM2 regulation in cis by a pseudo-substrate peptide
motif highlights the growing realization that many signal
transduction events are modulated by relatively small and
unstructured polypeptide motifs [27–29]. Although there
are many well-defined globular protein domains that form
folded independent compact structures, these globular
domains represent only a fraction of the cellular polypep-
tide sequence repertoire. The remaining peptide sequences
are intrinsically disordered and comprise linear motifs with
weaker binding kinetics. Thus, signal transduction among
many components interacting via linear peptide motifs with
weaker binding kinetics can provide specific and sensitive
regulation of cellular signal transduction processes. The
regulation of MDM2 by such a flexible motif highlights
how these motifs can impact signal transduction. Further
perturbations in these linear interaction motifs, for example
by covalent modifications like phosphorylation, have the
potential to drive signaling changes that mediate changes in
the protein–protein interaction dynamics central to signal
transduction. The ability of MDM2 to be modulated by a
flexible peptide motif opens the door to identify the
physiological signals that regulate this conformational
switch in MDM2 as well as potentially novel pathways
that respond to such an activated MDM2 conformation. For
example, if the MDM2-lid kinase were to be identified, it is
possible that this would promote p53 protein ubiquitination
and degradation in cells, and this lid-kinase pathway would
therefore function as a pro-oncogenic signal in cancers. By
contrast, protein phosphatases that antagonize this kinase
would be predicted to function as co-tumor suppressor of
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p53 function by attenuating MDM2-mediated ubiquitina-
tion of p53.
Conclusions: perspectives on potential drug leads
in the MDM2 pathway based on protein–protein
interactions in the ubiquitination system
The molecular and structural mechanisms of MDM3 E3-
RING domain-E2-mediated ubiquitination of p53 are only
beginning to be defined. Complex and dynamic protein–
protein interactions can be anticipated a priori. These include
firstly the allosteric intradomain interactions in MDM2 itself,
for example, highlighted by the fact that the RING domain
plays a role in regulating the conformation of the N-terminal
hydrophobic domain and the acidic domain [52]. It is striking
that specific mutations in the RING domain appear to open
the conformation of the acidic domain of MDM2 based on
elevated intrinsic tryptophan fluorescence. This suggests that
ligands that bind to the RING domain (like RNA, ATP, and
E2 ubiquitin–conjugating protein) would regulate the inter-
conversion between open and closed conformations of
MDM2 within the acidic domain. This might in turn modify
the type of small molecules acquired in screens for ligands
that bind to the acidic domain of MDM2 and inhibit p53
ubiquitination, i.e., reconstitution of the complete E2–E3–
p53 tetramer ubiquitination reaction using highly purified
proteins and with specific RING-domain co-factors will
likely affect the dynamics of the acidic domain conformation.
The ability of the phospho-mimetic MDM2 lid to stabilize
the MDM2:BOX-V peptide interaction (Fig. 10) further puts
focus on the acidic domain as a key site for developing small
ligands that disrupt MDM2 ubiquitination of p53.
The second protein–protein interaction to consider is the
undefined effect of E3-RING domain on the E2-mediated
enzymatic transfer of ubiquitin to the p53 substrate. Small
molecule first generation leads have already been identified
that disrupt substrate ubiquitination possibly by effecting E2
activity as well as E3 functions [54]. We do not know how E2
protein conformation is altered by E3-RING domain binding
and in turn how ligand binding at the RING domain of
MDM2 would alter the catalytic function of the E2 proteins.
The definition of E2–E3 interfaces using purified minido-
mains and then using the reconstituted ubiquitination system
would likely shed light on novel allosteric stages in this
multicomponent ubiquitination reaction. The third protein–
protein dynamic is the fact that the p53 protein is tetrameric,
and although it has at least two main binding sites for
MDM2, it is not clear how quaternary structure of p53
contributes to the valency of the MDM2:p53 interaction and
in turn what changes occur in p53 tetramers that allow E2-
dependent ubiquitination transfer to p53.
Although the N-terminal hydrophobic pocket of MDM2 is
a drug binding site, drug occupation at this site does not
inhibit p53 ubiquitination due to the allosteric nature of the
E3 ubiquitin ligase function of MDM2. However, the three
scenarios reviewed above provide biochemical approaches
with which to develop peptide-mimetic leads for disrupting
protein–protein interactions in the p53 substrate–E3–E2
enzymatic ubiquitination system. Additionally, if phosphor-
ylation in vivo of the MDM2 lid will be proven to stabilize
the interaction between the acidic domain of MDM2 and the
BOX-V peptide in the p53 DNA-binding domain, this would
drive p53 protein ubiquitination and degradation in cells.
The lid-kinase pathway itself would in turn provide a novel
approach for developing drug leads that attenuate MDM2-
mediated ubiquitination and degradation of p53 protein.
Fig. 8 A model of lid function through stabilization of the phospho-
mimetic motif on the surface of MDM2. a Multiple sequence
alignment of MDM2 and MDM4 highlighting the evolutionary
divergence between MDM2 and MDM4 at the potential pseudo-
substrate motif basic docking site for acidic residues (i.e., Asp,
phosphate) at amino acid residues 97–98. b The C-terminal region of
the pseudo-substrate domain (residues 18–24; colored yellow) can
have helical character and occupy the shallow end of the hydrophobic
binding pocket as reported previously [25]. The p53 peptide from
PDB structure 1YCR [20] is shown for comparison (colored orange).
The N-terminal p53 peptide sequence and the lid cannot occupy the
hydrophobic pocket simultaneously. c The pseudo-substrate motif can
also exist displaced from the binding pocket with Ser17 (S17D
mutation shown for illustration) in proximity to a basic region (see
d) at the N-terminal of helix α2′ composed of Arg97/Lys98. Based on
this, it is postulated that the S17D (mimicking phosphorylation of
Ser17) mutation could stabilize the N-terminal domain of MDM2 in a
conformation primed for p53 binding by forming electrostatic
interactions with residues Arg97/Lys98. e–g Effects of Arg97/Lys98
mutation on wild-type MDM2 activity. e MDM2 codon 97–98 residue
mutation to the MDM4 equivalent does not destabilize the MDM2:
p53 tetramer complex. Increasing amounts of the indicated MDM2
protein (wt-MDM2 or MDM2R97S:K98P) were titrated into reactions
where fixed amounts of tetrameric p53 were on solid phase as
described previously above. The extent of MDM2 binding was
quantified using an anti-MDM2 monoclonal antibody and binding
stability depicted using enhanced chemiluminescence in relative light
units (RLU). f The effects of MDM2 codon 97–98 residue mutation to
the MDM4 equivalent on MDM2:BOX-I peptide complex stability.
Increasing amounts of MDM2 protein (wt-MDM2 or the double mutant
MDM2R97S:K98P) were titrated into reactions with fixed amounts of the
BOX-I peptide on solid phase, as described previously above. The
extent of MDM2 binding was quantified using an anti-MDM2
monoclonal antibody and binding stability depicted using enhanced
chemiluminescence in relative light units (RLU). g The effects of
MDM2 codon 97–98 residue mutation to the MDM4 equivalent
on MDM2:BOX-V peptide complex stability. Increasing amounts of
MDM2 protein (wt-MDM2 or the double mutant MDM2R97S:K98P) were
titrated into reactions with fixed amounts of the BOX-V peptide on solid
phase, as described previously above. The extent of MDM2 binding
was quantified using an anti-MDM2 monoclonal antibody and binding
stability depicted using enhanced chemiluminescence in relative light
units (RLU)
b
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Materials and methods
Plasmids and site-directed mutagenesis
MDM2WT and MDM2ΔLid were cloned into the Invitrogen
Gateway system entry vector pDONR221 (Invitrogen)
using the following primers: full-length MDM2 Fwd 5′-
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGA
AGGAGATAGAACCAT GTGCAATACCAACATGT
CTGTACCTACT-3′ and Rev 5′-GGGGACCACTTTGTA
CAAGAAAGCTGGGTCCTAGGGGAAATAAGTTAG
CACAATCAT-3′: lid deletion MDM2 Fwd 5′- GGGGACA
AGTTTGTACAAAAAAGCAGGCTTCGAAGGAGATA
GAACCATGACCCTGGTTAGACCAAAGCCATTGCTT-
3′ and Rev—same as full length MDM2. This vector was
used as a template to perform site-directed mutagenesis
using the in vitro mutagenesis system QuikChange
(Stratagene) as directed by the manufacturer. MDM2
serine 17 was mutated to an aspartic acid using the
following primers (bases which introduce amino acid
change are in bold): amino acid 17 S>D Fwd 5′-
GGTGCTGTAACCACCGACCAGATTCCAGCTTCG-3′
and Rev 5′CGAAGCTGGA ATCTGGTCGGTGGTTA-
CAGCACC-3′. For native expression of protein in Escher-
ichia coli, pDONR221-MDM2 vectors were recombined with
the pDEST14 vector (Invitrogen) as recommended by the
manufacturer. For expression in mammalian cells, the
pDONR-MDM2 vectors were recombined with the
pDEST3.2 vector (Invitrogen). pDONR221-MDM2 was used
as a template to PCR clone MDM2ΔLid into pCDNA3.1 with
a
cb
d
Human MDM2 LFGVPSFSVKEHRKIYTMIYRNLVVVN
Mouse MDM2 VFGVPSFSVQEHRKIYTMIYRNLVAVS
Human MDM4 LLGRQSFSVKDPSPLYDMLRKNLVTLA
Mouse MDM4 LLGCQSFSVKDPSPLYDMLRKNLVTSA
85        95        105
β 2           α 4
Putative Lid 
Docking Site
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EcoR1 and Xho1 restriction sites. EcoR1 Fwd primer 5′-
GCCTCGAATTCATGACCCTGGTTAGAC CAAAGC-
CATTGCTT-3 ′ and Xho1 Rev 5 ′ - GCCTCGA
GCTCCTAGGGGAAATAAGTTAGCACAATCAT-3′.
pCDNA3.1 full length MDM2 was subjected to site-directed
mutagenesis as described before to introduce mutation at
serine 17 (S>D).
Protein expression and purification
pDEST14-MDM2 constructs were overexpressed in BL-21
arabinose-inducible E. coli for 3 h at room temperature.
Cells were harvested by centrifugation at 6,000×g for
10 min and frozen in liquid nitrogen. Bacterial pellet was
lysed in 10% sucrose, 50 mM Tris–HCl (pH8), 150 mM
NaCl, and 150μg/ml lysozyme and left on ice for 45 min
before sonication. After sonication, 2 mM Pefabloc, 5 mM
DTT, and 1 mM benzamidine was added to lysate before
centrifugation at 30,000×g for 20 min. Lysate was loaded
onto a fast flow SP column (GE Healthcare) equilibrated
with buffer A (25 mM Hepes, pH7.5, 10% glycerol, 1 mM
benzamidine, 5 mM DTT, 50 mM KCl, and 2 mM
Pefabloc). Bound protein was eluted with increasing salt
concentration using buffer B (same as buffer A but 1M
KCl) and MDM2 function measured in E3 ubiquitin ligase
assays.
MDM2-peptide and p53 protein binding activity assays
Recombinant human MDM2 protein, ubiquitination assays,
and p53 protein binding assays were developed as
described previously [38, 50]. For p53-peptide binding
assays, the plate was adsorbed with streptavidin overnight
and washed six times with PBS-T, and biotinylated peptides
were added for 1 h followed by titrating increasing amounts
of MDM2 (from 3 to 200 ng). Following further washes for
six times with PBS-T, wells were incubated with secondary
rabbit anti-mouse horseradish peroxidase antibodies fol-
lowed by further washing and ECL. The results were
quantified using Fluoroskan Ascent FL equipment (Lab-
systems) and analyzed with Ascent Software version 2.4.1
(Labsystems). Peptides BOXIa, BOXIb, BOXVa, and
BOXVb were from Chiron Mimetopes and Nutlin3a from
Alexis Biochemicals. Peptide sequences are as follows:
BOXIa - Biotin-SGSGPPLSQETFSDLWKLLP; BOXIb-
Biotin-SGSGMPRFMDYWEGLN; BOXVa-Biotin-SGS
GRNSFEVRVCACPGRD; BOXVb-Biotin-SGSGDQIM
MCSMYGICKVKNIDLK.
In vitro ubiquitination assay
Reactions contained 25 mM HEPES (pH8.0), 10 mM
MgCl2, 4 mM ATP, 0.5 mM DTT, 0.05% (v/v) Triton X-
Fig. 8 (continued)
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100, 0.25 mM benzamidine, 10 mM creatine phosphate,
3.5 units/ml creatine kinase, ubiquitin (2μg), E1 (100 nM),
E2 (1μM), and p53 (0.5μg). Reactions were assembled on
ice by adding, last, purified MDM2, MDM2Δlid, or
MDM2S17D at various concentrations (3–200 ng), followed
by incubations for 15 min at 30°C, and analyzed with 4–
12% NuPAGE gels in a MOPS buffer system (Invitrogen)
followed by immunoblot. For temperature gradient, MDM2
was subjected to heat treatment for 5 min prior to addition
to ubiquitination reaction.
Cell culture and purification of his-ubiquitin conjugates
H1299 cells were grown at 37°C in RPMI with 10% FBS and
5%CO2. p53
−/−MDM2−/− mouse embryonic fibroblasts were
grown in DMEM with 10% (v/v) FBS and 10% CO2.
MDM2 MDM4
R97/K98 S97/P98
a
b
c d e
Fig. 9 Inactivation of MDM2S17D by mutation of surface basic residues
of MDM2. a Electrostatic potential mapped onto the solvent accessible
surface. Positive- and negative-charged regions colored blue and red,
respectively. Alignment figure generated with ESPript [14]. Structural
figures generated with PyMol (www.pymol.org). The electrostatic
calculations were performed with APBS [3] and highlighted is (left)
wild-type MDM2 and (right) MDM2 with R97/K98 residues substituted
with the S97/P98 MDM4 residues. bWhen the basic patch on MDM2 is
mutated to Ser97/Pro98, the phospho-mimetic pseudo-substrate motif
may bind other basic regions of the MDM2 surface such as Lys94/His96,
which line the hydrophobic binding pocket and explain why the MDM2
triple mutant (MDM2S17D:R97S:K98P) binds p53 with a substantially
lower activity than does the MDM2 double mutant (MDM2R97S:K98P;
see c–e). c MDM2 codon 97–98 residue mutation to the MDM4
equivalent inactivates MDM2S17D as a p53 binding protein. Increasing
amounts of the indicated MDM2 protein (MDM2S17D or the triple
mutant MDM2S17D:R97S:K98P) were titrated into reactions where fixed
amounts of tetrameric p53 were on solid phase as described previously
above. The extent of MDM2 binding was quantified using an anti-
MDM2 monoclonal antibody and binding stability depicted using
enhanced chemiluminescence in relative light units (RLU). d The effects
of MDM2 codon 97–98 residue mutation to the MDM4 equivalent on
MDM2S17D:BOX-I peptide complex stability. Increasing amounts of
MDM2 protein (MDM2S17D or the triple mutant MDM2S17D:R97S:K98P)
were titrated into reactions with fixed amounts of the BOX-I peptide on
solid phase, as described previously above. The extent of MDM2
binding was quantified using an anti-MDM2 monoclonal antibody and
binding stability depicted using enhanced chemiluminescence in relative
light units (RLU). e The effects of MDM2 codon 97–98 residue
mutation to the MDM4 equivalent on MDM2S17D:BOX-V peptide
complex stability. Increasing amounts of MDM2 protein (MDM2S17D or
the triple mutant MDM2S17D:R97S:K98P) were titrated into reactions with
fixed amounts of the BOX-V peptide on solid phase, as described
previously above. The extent of MDM2 binding was quantified using an
anti-MDM2 monoclonal antibody and binding stability depicted using
enhanced chemiluminescence in relative light units (RLU)
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Transient transfections were carried out as described [10].
Cells were lysed in NP40 buffer (25 mM HEPES, pH7.5,
0.1% NP40, 150 mM KCl, 5 mM DTT, and 50 mM NaF)
and analyzed by 4–12% NuPAGE/immunoblot. His-ubiquitin
conjugates were purified as previously described [53].
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